zen-3694
Small moleculeexperimental
Clinical trial activity
12 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2020 (NCT04471974)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
Mechanism of action
- Myc proto-oncogene proteinINHIBITOR
MYC inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068600 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06922318 | Phase 2 | Aug 19, 2025 | Johns Hopkins University, National Cancer Institute (NCI), Zenith Epigenetics |
| NCT05950464 | Phase 1 | May 27, 2024 | National Cancer Institute (NCI), NRG Oncology |
| NCT06102902 | Phase 1 | Feb 16, 2024 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT05803382 | Phase 1 | Nov 8, 2023 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT05422794 | Phase 1 | Sep 30, 2022 | Harvard University, National Cancer Institute (NCI) |
| NCT05372640 | Phase 1 | Aug 12, 2022 | Harvard University, National Cancer Institute (NCI) |
| NCT05327010 | Phase 2 | Aug 4, 2022 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT05019716 | Phase 1/Phase 2 (Phase 2) | Apr 29, 2022 | Harvard University, National Cancer Institute (NCI) |
| NCT05053971 | Phase 1/Phase 2 (Phase 2) | Mar 11, 2022 | National Cancer Institute (NCI), Yale University |
| NCT05111561 | Phase 1 | Jan 17, 2022 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04840589 | Phase 1 | Oct 6, 2021 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT04471974 | Phase 2 | Dec 7, 2020 | Merck, United States Army, University of California, San Francisco, Zenith Epigenetics |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 11 | 10 | 2 | 2021 |
| Harvard University | Academic/Hospital | 3 | 0 | 2 | 2022 |
| University of Texas at Houston | Academic/Hospital | 3 | 0 | 2 | 2022 |
| University of Pittsburgh | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Zenith Epigenetics | For profit | 2 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2020 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| United States Army | Government | 1 | 0 | 1 | 2020 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2022 |
11 organizations
Page 1 / 1